Form 4: Ligand Pharmaceuticals Director Exercises Stock Options, Increases Direct Holdings

John W. Kozarich, a Director at Ligand Pharmaceuticals Inc., exercised stock options to acquire 2,406 shares of common stock at $52.3 per share, increasing his direct beneficial ownership to 46,181 shares.

Summary

• John W. Kozarich, a Director of Ligand Pharmaceuticals Inc. (LGND), executed a transaction on January 17, 2025.
• He exercised non-qualified stock options to acquire 2,406 shares of LGND common stock.
• The exercise price for these shares was $52.3 per share.
• Following this transaction, Mr. Kozarich's direct beneficial ownership of Ligand Pharmaceuticals common stock increased to 46,181 shares.
• The exercised option was previously part of a grant of 2,754 shares that vested on April 24, 2016, with an original exercise price of $89.75 per share, though the current exercise was at $52.3.
• The derivative securities (options) beneficially owned by Mr. Kozarich after this transaction are 0.

Sentiment

Score: 6

Explanation: The exercise of options by a director is generally seen as a positive signal of confidence, especially when the options are 'in the money'. However, it's a routine disclosure and doesn't provide significant new strategic or financial information.

Positives

• The exercise of stock options by a director indicates continued confidence in the company's future prospects.
• The director's direct beneficial ownership of common stock increased to 46,181 shares, aligning his interests further with shareholders.
• The exercise price of $52.3 is lower than the original grant price of $89.75, suggesting the option was 'in the money' at the time of exercise, which is favorable for the insider.

Future Outlook

This Form 4 filing is a report of an insider transaction and does not contain forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This Form 4 filing reports an individual insider transaction and does not provide broader industry context or trends. Insider transactions are common across all industries as part of executive compensation and personal investment strategies.

Comparison to Industry Standards

• This Form 4 filing reports a standard insider stock option exercise. Such transactions are common compensation mechanisms for directors and executives across publicly traded companies.
• There are no specific comparable companies or projects mentioned to assess against global benchmarks, as this is a routine individual transaction disclosure.

Related Party Transactions

• The transaction involves a director of Ligand Pharmaceuticals Inc. exercising stock options, which is a common form of related party transaction between an insider and the company.

Stakeholder Impact

• Shareholders: The increase in director's direct ownership aligns his interests more closely with shareholders, potentially signaling confidence in the company's future performance.
• Employees: No direct impact on employees is indicated by this transaction.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this transaction.

Key Dates

Recommendation

Keywords

Ligand Pharmaceuticals, LGND, SEC Form 4, Insider Trading, Stock Option Exercise, Beneficial Ownership, Director Transaction, Equity Compensation